iTi Health Inc, spun out of the University of Virginia, holds proprietary technology identifies a protein biomarker in the early stages of pancreatic cancer. iTi Healthâs platform technology, PHAGEMARKâ¢, rapidly identifies novel disease and drug-response targets. By focusing on the validation of its lead imaging product, Plectiscanâ¢, which detects the target for pancreatic cancer, known as plectin, iTi Health will address the at-risk population for this disease. iTi is an acronym for âidentify target image,â which describes the companyâs core ability to identify highâvalue biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. An extensively validated lead program centers on the protein target plectin, which is up-regulated on the cell surface specifically in pancreatic cancer, as well as in a growing list of m
